What is Compounded Semaglutide: Understanding the Personalized Approach to Weight Loss

Last reviewed: June 7, 2026

Last updated: June 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Compounded semaglutide is a preparation made by a licensed pharmacy for an individual patient against a valid prescription, using semaglutide purchased as a bulk drug substance. It is not an FDA-approved finished product, and the FDA is explicit that compounded drugs are not FDA-approved — the agency does not verify their safety, effectiveness or quality before they are marketed. It is also not a generic: a generic drug is approved under section 505(j) of the Act and must establish therapeutic equivalence to a brand-name drug, and no approved generic of any semaglutide product exists.

What Compounding Is

Compounding is the preparation of a medication for an individual patient, historically to meet a need an available manufactured product cannot — a different strength, the removal of an allergen, or a liquid form for someone unable to swallow a tablet. The FDA describes compounding as serving an important patient need when an FDA-approved drug is not medically appropriate for a patient.

Federal law addresses compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a physician, and separately by or under the direct supervision of a licensed pharmacist in an outsourcing facility. Outsourcing facilities are a category established in 2013 by the Drug Quality and Security Act, are inspected by the FDA on a risk-based schedule, and are subject to increased quality standards.

PlexusDx works with licensed 503A compounding pharmacies, which are the state-licensed pharmacy category operating under section 503A of the Act.

The Statutory Conditions That Govern It

Under section 503A, the bulk drug substances used must comply with the standards of an applicable United States Pharmacopeia or National Formulary monograph where one exists and with the USP chapter on pharmacy compounding; where no monograph exists, they must be components of drugs approved by the Secretary or appear on a list developed by regulation.

They must also be manufactured by an establishment registered with the FDA, including foreign establishments registered under section 510(i), and be accompanied by valid certificates of analysis for each bulk drug substance.

The section further prohibits compounding regularly or in inordinate amounts any drug product that is essentially a copy of a commercially available drug product, and prohibits compounding products that appear on the FDA list of drugs withdrawn or removed from the market for safety or effectiveness reasons.

What "Personalized" Legitimately Refers To

The honest meaning is narrow. A compounded preparation is made against an individual prescription rather than manufactured in advance for a general market, and a prescriber can specify a strength or a presentation that suits a particular clinical situation.

What it does not mean is that a preparation has been tailored to your biology in a way an approved product could not be, or that any tailoring improves outcomes. No trial has tested that proposition, and the FDA lists claims that a compounded drug is the same as an FDA-approved drug among its consumer red flags.

The prescriber, not the preparation, is the source of individualisation. The approved labels themselves direct that treatment response and tolerability be considered when selecting a maintenance dosage — clinical judgement applied over time.

The Molecule Is Not Automatically the Same

This is the substantive difference between compounded and approved semaglutide, and it is not theoretical. The FDA has stated that some semaglutide products sold by compounders may be salt forms including semaglutide sodium and semaglutide acetate, that these salt forms are different active ingredients than those used in the approved drugs, and that the agency does not have information on whether they share the same chemical and pharmacologic properties.

For reference, the approved product’s active ingredient is described in the Wegovy label: a peptide backbone produced by yeast fermentation, modified at position 8 against DPP-4 degradation and at position 26 with a hydrophilic spacer and a C18 fatty di-acid, molecular formula C187H291N45O59, molecular weight 4113.58 g/mol.

What Is Known About Risk in This Category

The FDA has received multiple reports of adverse events, some requiring hospitalisation, that may be related to dosing errors with compounded injectable semaglutide, arising from patients measuring and self-administering incorrect doses and from health care professionals miscalculating doses.

It has also received reports that may relate to compounded products being prescribed in doses beyond the approved labeling, documented fraudulent products carrying false pharmacy information on their labels, and received complaints of injectable products arriving warm or with inadequate refrigeration.

None of this describes the category as a whole. It describes documented failure modes, which is exactly what a patient needs in order to evaluate a specific source.

The Safety Profile of Semaglutide Applies Regardless

Everything the approved labels say about the molecule applies to any preparation containing it. The boxed warning on rodent thyroid C-cell tumors, the contraindications for personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2, and the warnings on pancreatitis, gallbladder disease, acute kidney injury due to volume depletion, hypoglycemia with insulin or secretagogues, severe gastrointestinal reactions and pulmonary aspiration under anesthesia are all properties of semaglutide.

The screening conversation with a prescriber is therefore identical in substance whichever category of product is under discussion.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What exactly is compounded semaglutide?

A preparation made by a licensed pharmacy for an individual patient against a valid prescription, using semaglutide purchased as a bulk drug substance rather than obtained as a finished manufactured product. The FDA states that compounded drugs are not FDA-approved and that the agency does not verify their safety, effectiveness or quality before they are marketed.

Is it a generic version of Wegovy or Ozempic?

No. The FDA addresses this directly: a generic drug is approved under section 505(j) of the Act and must meet that section’s requirements, including establishing therapeutic equivalence to a brand-name drug, while a compounded drug is not FDA-approved. There are no approved generic versions of any semaglutide product, so no compounded preparation can be one.

What does personalized actually mean here?

It means the preparation is made against an individual prescription rather than manufactured in advance for a general market, and that a prescriber can specify a strength or presentation suited to a clinical situation. It does not mean the formulation has been matched to your biology, and no trial has tested whether such tailoring improves outcomes.

Is the active ingredient identical to the approved product?

Not necessarily. The FDA has stated that some semaglutide products sold by compounders may be salt forms, including semaglutide sodium and semaglutide acetate, that these are different active ingredients than those used in the approved drugs, and that the agency lacks information on whether they share the same chemical and pharmacologic properties as the approved active ingredient.

Do the same warnings apply as for the brand products?

Yes, because they are properties of the molecule. The approved labeling carries a boxed warning on rodent thyroid C-cell tumors, contraindications for personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2, and warnings including pancreatitis, gallbladder disease, acute kidney injury from volume depletion and pulmonary aspiration under anesthesia.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.